Physician profile

Christina Adele Moore

Family · Kennewick, WA

NPI 1053850040

$1,055.12

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$111.90
Education$18.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
E.R. Squibb & Sons, L.L.C. $387.13 2021-2022
Glaxosmithkline, LLC. $225.00 2022
Astrazeneca Pharmaceuticals LP $111.90 2023 Enhertu
Ipsen Biopharmaceuticals, INC $105.19 2022
Jazz Pharmaceuticals INC. $97.45 2022
Janssen Biotech, INC. $71.86 2022
Incyte Corporation $21.60 2022
Pfizer INC. $18.00 2024
Exelixis INC. $16.99 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Christina Adele Moore

$1,055.12

in general payments reported 2019-2025

Years
2021-2024
Top company
E.R. Squibb & Sons, L.L.C.

https://glasscript.com/doctor/10466764/christina-adele-moore

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.